Outcomes Following Bone Marrow Transplantation in Children with Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors

David S. Shulman, Michelle A. Lee, Leslie E. Lehmann, Steven P. Margossian

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The management of chronic myelogenous leukemia (CML) in children changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs). Unfortunately, outcomes for patients presenting in an advanced stage - accelerated phase or blast crisis CML - continues to be poor, requiring chemotherapy and allogeneic hematopoietic stem cell transplant (HSCT) to attempt cure. Integration of TKIs in the therapy of advanced CML is still an area of active investigation. There are little published data on TKI use in children with advanced stage CML. We performed a retrospective review of all children treated at our institution between January 1, 2010 and June 30, 2013, and identified 5 children, age 12 to 18 years, with advanced stage CML. All patients were treated with a TKI before HSCT and TKIs were restarted post-HSCT in 4/5 with a goal of continuing until 2 years posttransplant. At time of HSCT all were in a morphologic and cytogenetic remission; 1 patient had also achieved molecular remission. All patients are alive and in molecular remission at an average of 38 months (range, 14 to 51 mo) following transplant. Our experience indicates that TKIs are safe and well tolerated in children both pretransplant and posttransplant and may improve outcomes in this aggressive disease.

Original languageEnglish (US)
Pages (from-to)610-614
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume38
Issue number8
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Protein-Tyrosine Kinases
Hematopoietic Stem Cells
Transplants
Cytogenetics
Drug Therapy

Keywords

  • bone marrow transplant
  • chronic myelogenous leukemia
  • hematopoietic cell transplant
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Outcomes Following Bone Marrow Transplantation in Children with Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. / Shulman, David S.; Lee, Michelle A.; Lehmann, Leslie E.; Margossian, Steven P.

In: Journal of Pediatric Hematology/Oncology, Vol. 38, No. 8, 01.11.2016, p. 610-614.

Research output: Contribution to journalArticle

@article{71abfe676b8c416abd593690bea13174,
title = "Outcomes Following Bone Marrow Transplantation in Children with Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors",
abstract = "The management of chronic myelogenous leukemia (CML) in children changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs). Unfortunately, outcomes for patients presenting in an advanced stage - accelerated phase or blast crisis CML - continues to be poor, requiring chemotherapy and allogeneic hematopoietic stem cell transplant (HSCT) to attempt cure. Integration of TKIs in the therapy of advanced CML is still an area of active investigation. There are little published data on TKI use in children with advanced stage CML. We performed a retrospective review of all children treated at our institution between January 1, 2010 and June 30, 2013, and identified 5 children, age 12 to 18 years, with advanced stage CML. All patients were treated with a TKI before HSCT and TKIs were restarted post-HSCT in 4/5 with a goal of continuing until 2 years posttransplant. At time of HSCT all were in a morphologic and cytogenetic remission; 1 patient had also achieved molecular remission. All patients are alive and in molecular remission at an average of 38 months (range, 14 to 51 mo) following transplant. Our experience indicates that TKIs are safe and well tolerated in children both pretransplant and posttransplant and may improve outcomes in this aggressive disease.",
keywords = "bone marrow transplant, chronic myelogenous leukemia, hematopoietic cell transplant, tyrosine kinase inhibitor",
author = "Shulman, {David S.} and Lee, {Michelle A.} and Lehmann, {Leslie E.} and Margossian, {Steven P.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1097/MPH.0000000000000636",
language = "English (US)",
volume = "38",
pages = "610--614",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Outcomes Following Bone Marrow Transplantation in Children with Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors

AU - Shulman, David S.

AU - Lee, Michelle A.

AU - Lehmann, Leslie E.

AU - Margossian, Steven P.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The management of chronic myelogenous leukemia (CML) in children changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs). Unfortunately, outcomes for patients presenting in an advanced stage - accelerated phase or blast crisis CML - continues to be poor, requiring chemotherapy and allogeneic hematopoietic stem cell transplant (HSCT) to attempt cure. Integration of TKIs in the therapy of advanced CML is still an area of active investigation. There are little published data on TKI use in children with advanced stage CML. We performed a retrospective review of all children treated at our institution between January 1, 2010 and June 30, 2013, and identified 5 children, age 12 to 18 years, with advanced stage CML. All patients were treated with a TKI before HSCT and TKIs were restarted post-HSCT in 4/5 with a goal of continuing until 2 years posttransplant. At time of HSCT all were in a morphologic and cytogenetic remission; 1 patient had also achieved molecular remission. All patients are alive and in molecular remission at an average of 38 months (range, 14 to 51 mo) following transplant. Our experience indicates that TKIs are safe and well tolerated in children both pretransplant and posttransplant and may improve outcomes in this aggressive disease.

AB - The management of chronic myelogenous leukemia (CML) in children changed dramatically with the introduction of tyrosine kinase inhibitors (TKIs). Unfortunately, outcomes for patients presenting in an advanced stage - accelerated phase or blast crisis CML - continues to be poor, requiring chemotherapy and allogeneic hematopoietic stem cell transplant (HSCT) to attempt cure. Integration of TKIs in the therapy of advanced CML is still an area of active investigation. There are little published data on TKI use in children with advanced stage CML. We performed a retrospective review of all children treated at our institution between January 1, 2010 and June 30, 2013, and identified 5 children, age 12 to 18 years, with advanced stage CML. All patients were treated with a TKI before HSCT and TKIs were restarted post-HSCT in 4/5 with a goal of continuing until 2 years posttransplant. At time of HSCT all were in a morphologic and cytogenetic remission; 1 patient had also achieved molecular remission. All patients are alive and in molecular remission at an average of 38 months (range, 14 to 51 mo) following transplant. Our experience indicates that TKIs are safe and well tolerated in children both pretransplant and posttransplant and may improve outcomes in this aggressive disease.

KW - bone marrow transplant

KW - chronic myelogenous leukemia

KW - hematopoietic cell transplant

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84978121086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978121086&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000636

DO - 10.1097/MPH.0000000000000636

M3 - Article

VL - 38

SP - 610

EP - 614

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 8

ER -